University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled OXPHOS, AML M5 Is a Risk Factor for Lack of Response to Venetoclax

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Daniel Pollyea
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Daniel Pollyea
30 views
May 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
AML Biology and Treatment
20:35

Curing APL in 2020: Have We Completely Deciphered Mechanism(s) of Co…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Tallman

61 views
16:42

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

University of Miami's 2nd Biennial Miami Leukemia Symposium

E. Stein

228 views
20:28

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Guzman

23 views
23:05

Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled…

University of Miami's 2nd Biennial Miami Leukemia Symposium

D. Pollyea

30 views